Success Story

Neuralert receives important FDA Breakthrough Designation

Neuralert, a Penn Medicine startup founded by Steven Messé, MD (Department of Neurology) and James Weimer, PhD (Department of Computer and Information Science) addresses the problem of late or undetected stroke in hospitalized patients. The founders invented technology that uses non-invasive, wearable devices which continuously monitor at-risk hospitalized patients for stroke symptoms and automatically alerts clinical staff resulting in more rapid assessment and treatment of the patient. The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has granted the Neuralert Monitor designation as a Breakthrough Device. The Neuralert Technologies device is indicated for use to “detect the onset of asymmetric movement in hospitalized patients with medical conditions or procedures that are established risks for stroke and who have no baseline asymmetric upper extremity weakness.”

Skip to content